GSK has supplied its anti-viral, Relenza ® (zanamivir for inhalation), to the U.S. government and is now working with private-sector businesses and other organizations to provide Relenza ® as part of their business continuity planning.
A new agreement with the Simcere Pharmaceutical Group of Nanjing, China, granting Simcere the right to manufacture and sell the anti-viral influenza treatment zanamivir in China, Indonesia, Thailand, Vietnamand all Least Developed Countries.